NFCR commits $1 million in financing to Rasio Therapeutics to develop treatments targeting cancers with limited treatment options
November 25, 2019, Baltimore, MD – Rasio Therapeutics, Inc., a biopharmaceutical company that develops novel medicines using cutting-edge computer-aided drug design technology, today announced the launch of a formal partnership with the National Foundation for Cancer Research (NFCR).
As part of the new partnership, NFCR has committed $1 million in financing to Rasio to advance a unique pipeline of therapeutics for the treatment of cancer. Rasio will use its exclusive partnership with SilcsBio, LLC to design and develop drugs for previously inaccessible targets implicated in cancer.
NFCR is a nonprofit organization, based in Rockville, MD, that provides funding to companies and scientists to make discoveries in cancer treatments, detection, prevention and ultimately, a cure. NFCR emphasizes long-term, transformative research often overlooked by other major funding sources.
“Our partnership with NFCR and its talented network of researchers gives us an incredible opportunity to implement our unique drug discovery process to benefit cancer patients,” said Todd Chappell, CEO of Rasio. “NFCR is one of the few organizations willing to make investments in early-stage companies and we are grateful for their support. Our collaboration with NFCR will be critical for advancing our common mission to develop meaningful and transformative treatments for cancer patients.”
NFCR, under the partnership terms, is providing Rasio access to its world renowned, global network of investigators. Rasio aims to leverage these resources to solve typically difficult-to-drug targets and efficiently deliver high quality, small molecule drug candidates. These targets include emerging and well-validated targets that have proven to be intractable to the pharmaceutical industry.
“Our mission at NFCR is to support high-potential, early-stage companies developing therapies poised to benefit cancer patients,” said Sujuan Ba, PhD, NFCR President and CEO. “We're very glad to partner with Rasio Therapeutics to help access new therapeutic targets through its computational chemistry platform and expedite the drug development process.”
As part of its current growth phase, Rasio recently named as CEO Todd Chappell, a 20-year veteran of the biopharma industry. Mr. Chappell is a seasoned early-stage life science entrepreneur who has led programs at multiple companies, including CombinatoRx, Shape Pharmaceuticals and Perceptive Navigation, from discovery stage through to clinical trials.
About Rasio Therapeutics:
Rasio Therapeutics, Inc., is a Maryland-based biopharmaceutical company that develops novel medicines using a cutting edge-computer-aided drug design technology. Rasio has partnered with SilcsBio, LLC, a leader in computational drug discovery, to develop small molecules for exciting but previously inaccessible disease targets. Rasio is initially focusing on oncology and has raised seed funding to design and develop several oncology therapeutics for areas of significant unmet medical need. For more information, visit: www.rasiotx.com
About the National Foundation for Cancer Research:
The National Foundation for Cancer Research (NFCR) is a 501(c)(3) non-profit organization that provides scientists in the lab the funding they need to make and apply game-changing discoveries in cancer treatment, detection, prevention and, ultimately, a cure. It has distinguished itself in the cancer sector by emphasizing long-term, transformative research often overlooked by other major funding sources. With the help of more than 5.3 million individual donors over the last 46 years, NFCR has delivered more than $380 million in funding cancer research and cancer prevention education, leading to several important, life-saving discoveries. For more information, visit: www.nfcr.org
Ken Malone, Rasio Therapeutics
Comments are closed.